Back to search results

Study for Isolated Skin Vasculitis

This study is testing three standard treatments for isolated skin vasculitis, a condition where blood vessels in the skin become inflamed. The treatments being compared are colchicine, dapsone, and azathioprine. The study aims to see how well these drugs work to treat your skin vasculitis. You might be able to join if you are 18 or older and have primary skin vasculitis that doesn't involve other parts of your body, such as isolated cutaneous small or medium-sized vessel vasculitis, cutaneous polyarteritis nodosa (PAN), or IgA vasculitis. The study is looking for 90 participants, but its current status is unclear.

Study design
This is a multi-center randomized study, meaning participants are randomly assigned to one of three treatments. It involves 90 planned participants.
What's involved
You would take one of the study medications for 6 months. If that medication doesn't work or causes side effects, you might be randomized again to a different medication for another 6 months.
Compensation
Not stated in the trial record.
Follow-up
You will be followed for response to treatment at 6 months. If you switch medications, you will be followed for another 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02939573

A Randomized Multicenter Study for Isolated Skin Vasculitis

Recruiting
PHASE2Ages 18+InterventionalTreatment
University of Pennsylvania
~90 participants
Updated 2026-08-20 on ClinicalTrials.gov
What's tested:ColchicineDapsoneAzathioprine

At a glance

Recruiting sites
7 of 16 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Efficacy of the study drugs for the treatment of skin vasculitis.
Measured over Response to therapy at month 6 of the pooled study stages 1 and 2.

Conditions

Primary Cutaneous Vasculitis
Cutaneous Polyarteritis Nodosa
IgA Vasculitis
Henoch-Schönlein Purpura

Explore related trials

Cutaneous Polyarteritis NodosaCutaneous VasculitisHenoch-Schönlein Purpura

Where it's being run

16 sites across 13 states
New York2
Pennsylvania2
Ontario2
Kansas1
Massachusetts1
Minnesota1
Ohio1
Tennessee1

Study leadership

  • Robert Micheletti, MD · STUDY_CHAIR · University of Pennsylvania
  • Christian Pagnoux, MD, MPH, MSc · STUDY_CHAIR · University of Toronto/Mount Sinai Hospital

Who to contact

Carol McAlear, MA
[email protected]
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Isolated cutaneous small vessel (SV) or medium-sized vessel (MV) vasculitis or cutaneous polyarteritis nodosa (PAN)
IgA vasculitis (IgA, formerly Henoch-Schönlein purpura), without active and/or progressing renal involvement (stable glomerular filtration rate (GFR) \>60 ml/min; absence of, or mild-and-stable microscopic hematuria without red blood cell casts; absence of, or mild-and-stable proteinuria (\<1g/24 hours); not requiring systemic immunosuppressive therapy).

What this trial measures

  • Efficacy of the study drugs for the treatment of skin vasculitis.Response to therapy at month 6 of the pooled study stages 1 and 2.

    Compare response to therapies.